Centrus Energy stock is surging to fresh highs after the uranium enricher unveiled a multibillion-dollar plan to expand its Piketon, Ohio plant. Shares of LEU jumped more than 13% to a 52-week high near 318 intraday, extending a week-to-date rally of roughly 21% as investors bet on an acceleration in domestic uranium enrichment and a bigger role supplying fuel for next-generation reactors.
The tape shows classic momentum. LEU punched through prior resistance to a new 52-week high of 318.08, up from a previous close of 276. The trigger: Centrus’ plan to scale both low-enriched uranium and high-assay low-enriched uranium capacity at Piketon, the only U.S. facility currently licensed and operating to produce HALEU at industrial scale. The move is landing as traders lean into nuclear-exposed names and as policy tailwinds brighten for domestic fuel supply.
The stock has been a rocket all year. Management’s latest update adds fresh fuel, but it also pushes valuation deeper into rare air. LEU now trades at a substantial premium to its own history, with a multiple of roughly 40 times operating cash flow versus a five-year average near 7. The shares have climbed more than 300% year to date by some measures. Bulls see structural scarcity and policy support. Skeptics see execution risk and a financing overhang.
Centrus’ plan centers on boosting throughput for LEU and HALEU, the latter a higher-assay fuel that several small modular reactor designs will require. Management did not put a capacity figure on the expansion, saying scope will depend on funding decisions from the Department of Energy tied to both LEU and HALEU programs. That caveat matters. The project’s size, speed, and capital intensity hinge on federal awards that could stagger or scale the build-out.
Ohio’s governor, Mike DeWine, framed the strategic angle in a statement backing the expansion, calling Piketon the only technology in place today capable of scaling domestic enrichment to industrial levels. For investors, that positioning is the story: a scarce asset in a critical link of the nuclear fuel cycle at a moment when the U.S. is trying to de-risk supply chains and accelerate new nuclear builds.
Centrus has line of sight on financing and demand, at least on paper. Over the past year the company raised more than 1.2 billion dollars via two convertible note deals and said it secured more than 2 billion dollars in contingent purchase commitments from customers. Those commitments suggest a market willing to lock in future volume and support capital deployment, especially for HALEU where global supply is thin.
The balance sheet has also benefited from better operations. In the second quarter, Centrus reported 28.9 million dollars of net income on 154.5 million dollars of revenue, topping expectations. The convertible structure does introduce dilution risk if shares keep climbing. It also places a premium on flawless execution to turn purchase commitments into cash flow as capacity comes online. Investors will want a clear schedule for when committed volumes shift to firm offtake with delivery and price terms.
The backdrop is unusually supportive. Washington has moved to cut reliance on Russian enriched uranium following new restrictions passed in 2024, pressing the case for domestic capacity. The White House has sharpened its focus on expanding the nuclear fleet and hardening the fuel cycle, and DOE has been running competitions and cost-shared awards to stand up HALEU supply. Centrus has already demonstrated production at Piketon and sits at the front of the line for scaled volumes if federal funding and market demand align.
At the same time, the private market is telegraphing future need. Multiple SMR developers say they require HALEU to meet mid-decade schedules. Utilities are restocking conventional uranium and enrichment services amid a multi-year rebound in nuclear load factors. Put differently: policy is the accelerant, but commercial pull is real. That combination is why uranium enrichment capacity is getting priced like a growth story, not a commodity cycle.
The risk is that expectations are now ahead of execution. Enrichment expansions run on long lead times, specialized equipment, and strict regulatory oversight. Capital needs will grow as scope increases. A premium multiple is defensible if Centrus converts contingent sales into multi-year, take-or-pay contracts and hits milestones on time. It gets tougher if DOE awards slip, if SMR timelines stretch, or if conventional reactor demand shifts back to incumbents abroad.
There is also financing nuance. Convertible notes helped secure capital at attractive rates for a company at Centrus’ scale, but they cap upside if investors worry about eventual share issuance. Add in the concentration risk of a single flagship site, and the path to justify today’s price requires visible, sequential progress: firm contracts, construction permits, cascade installations, and audited production growth quarter over quarter.
Two near-term markers matter most. First, DOE funding decisions tied to LEU and HALEU programs and any related offtake framework. Those awards will dictate capacity scope and timing. Second, disclosures from Centrus on capex, targeted output add, and the cadence for ramping new cascades at Piketon. Investors need a clearer bridge from today’s commitments to next year’s deliveries.
Beyond that, keep an eye on reactor developers’ procurement timelines, any additional U.S. restrictions on Russian nuclear fuel, and price action in uranium and enrichment services. A firmer pricing environment can pull forward returns on invested capital. Conversely, delays in SMR project schedules or policy drifts could elongate payback. Watch for updates from Ohio officials and federal agencies that could accelerate permitting or provide infrastructure support at the site.
Momentum is in charge, and the narrative is clean: a unique U.S. asset, multibillion-dollar growth, policy tailwinds, and rising demand for advanced nuclear fuel. That cocktail attracts capital in a market starved for scarce growth. But the math still has to work. With shares at a 52-week high and trading well above historical cash flow multiples, Centrus needs to deliver a steady cadence of contract conversions, funding wins, and capacity milestones to sustain the re-rating.
For now, the expansion headlines are doing their job. The next phase is execution. If Centrus locks down DOE-backed funding, inks additional firm offtakes, and details a credible ramp at Piketon, the stock can grow into its multiple. If not, the same scarcity premium that lifted LEU could prove fragile. Investors will not wait long for proof points.
